Immunomic Therapeutics (ITI) and Lysosomal Associated Membrane Protein (LAMP) Based Nucleic Acid Immunotherapy Featured At 2016 World Vaccine Congress

HERSHEY, Pa. and ROCKVILLE, Md., March 29, 2016 /PRNewswire/ -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing next-generation immunotherapy platforms will be participating at the World Vaccine Congress taking March 29 to 31, 2016 in Washington DC.

ITI chief executive officer Bill Hearl, PhD will be participating in a panel that will discuss collaborative research and partnering efforts with large pharmaceutical companies.  Dr. Hearl's participation follows an announcement last year of an exclusive worldwide licensing agreement with Astellas Pharma Inc. on LAMP-based immunotherapy for the treatment or prevention of any and all allergic diseases for people.  The panel entitled "Big Pharma Industry's external collaborative research and partnering opportunities for vaccine development" will also feature executives from Merck, Sanofi Pasteur and Takeda.  The panel will take place at 9:10 AM ET on Wednesday, March 30, 2016.

Additionally, an mRNA transfected dendritic cell immunotherapy employing pp65 and LAMP will also be discussed as a platform in oncology by Duane Anthony Mitchell, M.D., Ph.D., director at the University of Florida Tumor Immunotherapy Program in the Department of Neurosurgery.  Dr. Mitchell's presentation, entitled "LAMP-modified RNA-loaded dendritic cell vaccines for glioblastoma," will present data on the use of a LAMP-pp65 based nucleic acid immunotherapy to activate the immune system against cancer. To date, nucleic acid immunotherapies employing LAMP have been studied in early phase studies for glioblastoma multiforme, acute myeloid leukemia and metastatic melanoma. Dr. Mitchell's presentation will take place at 10:10 AM ET on Wednesday, March 30, 2016.

"We are pleased to participate again in this important meeting and to share our perspectives on collaborative drug research and development to make cutting edge advances available to patients as quickly as possible," said Dr. William G. Hearl, chief executive officer of ITI.  "It's also exciting to see LAMP-based nucleic acid immunotherapy move forward in clinical studies as a way to potentially create new and amplify immune responses to cancers."

About LAMP-based Nucleic Acid Immunotherapy and Immunomic Therapeutics

LAMP encodes the Lysosomal Associated Membrane Protein.  This allows nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural biochemistry, with the aim of developing a complete immune response including antibody production, cytokine release and critical immunological memory.  The ability to activate a complete immune response could give LAMP technology potential across a number of diseases, including cancer immunotherapy, allergy and infectious diseases.

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These disruptive technologies have the potential to fundamentally improve how we use immunotherapy for cancer, allergies and animal health.  Headquartered in Hershey, PA with lab facilities in Rockville, MD, ITI has entered into a significant licensing agreement with Astellas Pharma Inc., to explore the use of LAMP-vax, a next-generation immunotherapy platform, for use to prevent and treat allergic diseases. ITI believes that LAMP-based nucleic acid immunotherapy may have the potential to broaden the current use of cancer immunotherapy.  Preclinical data is currently being developed to explore how LAMP nucleic acid constructs could both amplify and activate the immune response in highly immunogenic tumor types and also be used to create  robust immune responses to tumor types that otherwise do not provoke an immune response. For information about ITI and LAMP Technology, visit www.immunomix.com.

SOURCE Immunomic Therapeutics, Inc.

Related Links

http://www.immunomix.com